Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1
- 1 March 1995
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 49 (7), 929-939
- https://doi.org/10.1016/0006-2952(95)00010-w
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Pharmacokinetics of an Antisense Phosphorothioate Oligodeoxynucleotide againstrevfrom Human Immunodeficiency Virus Type 1 in the Adult Male Rat Following Single Injections and Continuous InfusionAntisense Research and Development, 1994
- In VivoToxicological Effects ofrelA Antisense Phosphorothioates in CD-1 MiceAntisense Research and Development, 1994
- Large-Scale Synthesis, Purification, and Analysis of Oligodeoxynucleotide PhosphorothioatesAntisense Research and Development, 1994
- A mathematical model of the kinetics and tissue distribution of 2-fluoro-β-alanine, the major catabolite of 5-fluorouracilBiochemical Pharmacology, 1993
- Pharmacokinetics, Biodistribution, and Stability of Capped Oligodeoxynucleotide Phosphorothioates in MiceAntisense Research and Development, 1993
- GEM* 91—An Antisense Oligonucleotide Phosphorothioate as a Therapeutic Agent for AIDSAntisense Research and Development, 1992
- Characteristics of pharmacokinetic modelling in a phase I clinical trial of radiolabeled monoclonal antibodyControlled Clinical Trials, 1991